摘要
目的探讨福辛普利和缬沙坦对伴有高血压的代谢综合征患者的多环节干预作用及两者干预效果的差异。方法选择伴有高血压的代谢综合征患者60例,随机分配入福辛普利组(n=29)和缬沙坦组(n=31),治疗前及治疗后8周检测患者的血压、血脂、胰岛素抵抗指数(HOMR-IR)、血浆纤维蛋白原及高敏C反应蛋白。结果组内比较,两组患者治疗前、后血压、胰岛素抵抗指数、血浆纤维蛋白原及高敏C反应蛋白均值间差别均有显著性意义(P<0.05);治疗前、后缬沙坦组患者TC、LDL-C及TG均值间差别均有显著性意义(P<0.05);组间比较,两组患者胰岛素抵抗指数间差别有显著性意义(P<0.05),TC、LDL-C及TG均值间差别亦有显著性意义(P<0.05)。结论福辛普利和缬沙坦对伴有高血压的代谢综合征患者均有多环节干预作用。
Objective To investigate the effects of fosinopril and valsartan in hypertensive patients with metabolic syndrome （MS）. Methods Sixty hypertensive patients with MS were randomly divided as fosinopril - treated group （n = 29） and valsartan-treated group （n = 31）. The levels of blood pressure （Bp）, the homeostasis model assessment of insulin resistance （HOMA - IR）, fibrinogen （FIB, high - sensitivity C reactive protein （hs - CRP） and serum lipid were measured before and after 8 weeks treatment. Results Fosinopril and valsartan both significantly decreased the levels of BP, HOMA - IR, FIB and hs - CRP （P 〈 0.05）. Only valsartan - treated group showed statistically significant decrease in TC, LDL - C and TG level （P 〈 0.05）. Compared between two groups, there were a more obvious decrease in HOMA - IR level in fosinopril - treated group （P 〈 0.05） and a more obvious decrease in TC, LDL - C and TG level in valsartan - treated group （P 〈 0.05）. Conclusion Both fosinopril and valsartan both are of intervention in many ways in treatment of hypertensive subjects with metabolic syndrome.
出处
《中国全科医学》
CAS
CSCD
2006年第5期382-384,共3页
Chinese General Practice
